Education
About Us
Working with TipRanks
Follow Us
Nectar Lifesciences Ltd. (IN:NECLIFE)
:NECLIFE
RESEARCH TOOLSreports
Total Valuation
Nectar Lifesciences Ltd. has a market cap or net worth of ₹3.54B. The enterprise value is ₹15.10B.
Market Cap₹3.54B
Enterprise Value₹15.10B
Share Statistics
Nectar Lifesciences Ltd. has 224,260,970 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding224,260,970
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Nectar Lifesciences Ltd.’s return on equity (ROE) is -0.12 and return on invested capital (ROIC) is -4.04%.
Return on Equity (ROE)-0.12
Return on Assets (ROA)-0.06
Return on Invested Capital (ROIC)-4.04%
Return on Capital Employed (ROCE)-0.09
Revenue Per Employee9.90M
Profits Per Employee-958.09K
Employee Count1,686
Asset Turnover0.82
Inventory Turnover1.98
Valuation Ratios
The current PE Ratio of Nectar Lifesciences Ltd. is 30.0. Nectar Lifesciences Ltd.’s PEG ratio is ―.
PE Ratio30.0
PS Ratio―
PB Ratio―
Price to Fair Value0.56
Price to FCF―
Price to Operating Cash Flow0.00
PEG Ratio―
Income Statement
In the last 12 months, Nectar Lifesciences Ltd. had revenue of 16.70B and earned -1.14B in profits. Earnings per share was -5.07.
Revenue16.70B
Gross Profit3.02B
Operating Income-888.47M
Pretax Income-1.62B
Net Income-1.14B
EBITDA-245.66M
Earnings Per Share (EPS)-5.07
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Nectar Lifesciences Ltd. pays an annual dividend of ₹4.319, resulting in a dividend yield of ―
Dividend Per Share₹4.319
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.72
52-Week Price Change-59.50%
50-Day Moving Average18.45
200-Day Moving Average27.56
Relative Strength Index (RSI)46.26
Average Volume (3m)112.13K
Important Dates
Nectar Lifesciences Ltd. upcoming earnings date is Nov 13, 2025, TBA (Confirmed).
Last Earnings DateAug 14, 2025
Next Earnings DateNov 13, 2025
Ex-Dividend DateSep 11, 2020
Financial Position
Nectar Lifesciences Ltd. as a current ratio of 1.21, with Debt / Equity ratio of 60.87%
Current Ratio1.21
Quick Ratio0.54
Debt to Market Cap1.08
Net Debt to EBITDA-22.91
Interest Coverage Ratio-1.19
Taxes
In the past 12 months, Nectar Lifesciences Ltd. has paid -478.53M in taxes.
Income Tax-478.53M
Effective Tax Rate0.30
Enterprise Valuation
Nectar Lifesciences Ltd. EV to EBITDA ratio is -22.91, with an EV/FCF ratio of 4.48.
EV to Sales0.34
EV to EBITDA-22.91
EV to Free Cash Flow4.48
EV to Operating Cash Flow3.32
Balance Sheet
Nectar Lifesciences Ltd. has ₹187.35M in cash and marketable securities with ₹0.00 in debt, giving a net cash position of -₹187.35M billion.
Cash & Marketable Securities₹187.35M
Total Debt₹0.00
Net Cash-₹187.35M
Net Cash Per Share-₹0.84
Tangible Book Value Per Share₹40.12
Margins
Gross margin is 15.72%, with operating margin of -5.32%, and net profit margin of -6.81%.
Gross Margin15.72%
Operating Margin-5.32%
Pretax Margin-9.67%
Net Profit Margin-6.81%
EBITDA Margin-1.47%
EBIT Margin-5.21%
Analyst Forecast
The average price target for Nectar Lifesciences Ltd. is ₹14.50, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target₹14.50
Price Target Upside-8.17% Downside
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast-3.41%
EPS Growth Forecast-3028.15%